IL120943A - מערכת למתן תרופות דרך העור - Google Patents

מערכת למתן תרופות דרך העור

Info

Publication number: IL120943A
Authority: IL; Israel
Prior art keywords: insulin; skin; transdermal delivery; delivery system; iodine
Prior art date: 1997-05-29

Application number

IL12094397A

Other languages

English (en)

Other versions

IL120943A0 (en

Inventor

Amnon Sintov

Uri Wormser

Original Assignee

Univ Ben Gurion

Uri Wormser

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-29

Filing date

1997-05-29

Publication date

2004-03-28

1997-05-29 Application filed by Univ Ben Gurion, Uri Wormser filed Critical Univ Ben Gurion

1997-05-29 Priority to IL12094397A priority Critical patent/IL120943A/he

1997-09-30 Publication of IL120943A0 publication Critical patent/IL120943A0/xx

1998-05-04 Priority to US09/424,525 priority patent/US6274166B1/en

1998-05-04 Priority to AU70770/98A priority patent/AU7077098A/en

1998-05-04 Priority to JP50043099A priority patent/JP2002501524A/ja

1998-05-04 Priority to DE69832055T priority patent/DE69832055T2/de

1998-05-04 Priority to EP98917589A priority patent/EP0975357B1/en

1998-05-04 Priority to PCT/IL1998/000205 priority patent/WO1998053847A1/en

2001-08-10 Priority to US09/928,131 priority patent/US6667052B2/en

2004-03-28 Publication of IL120943A publication Critical patent/IL120943A/he

Links

230000037317 transdermal delivery Effects 0.000 title claims abstract description 15
239000007800 oxidant agent Substances 0.000 claims abstract description 21
102000004169 proteins and genes Human genes 0.000 claims abstract description 21
108090000623 proteins and genes Proteins 0.000 claims abstract description 21
239000000203 mixture Substances 0.000 claims abstract description 17
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 15
239000004480 active ingredient Substances 0.000 claims abstract description 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 181
108090001061 Insulin Proteins 0.000 claims description 90
102000004877 Insulin Human genes 0.000 claims description 90
229940125396 insulin Drugs 0.000 claims description 90
229920000153 Povidone-iodine Polymers 0.000 claims description 25
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 24
229960001621 povidone-iodine Drugs 0.000 claims description 24
108010082714 Silver Proteins Proteins 0.000 claims description 15
150000002978 peroxides Chemical class 0.000 claims description 4
239000000853 adhesive Substances 0.000 claims description 2
230000001070 adhesive effect Effects 0.000 claims description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
LAXXPOJCFVMVAX-ZETCQYMHSA-N (2s)-2-amino-4-butylsulfanylbutanoic acid Chemical compound CCCCSCC[C@H](N)C(O)=O LAXXPOJCFVMVAX-ZETCQYMHSA-N 0.000 claims 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
229910052700 potassium Inorganic materials 0.000 claims 1
239000011591 potassium Substances 0.000 claims 1
KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 abstract description 2
210000003491 skin Anatomy 0.000 description 69
241000700159 Rattus Species 0.000 description 34
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 31
239000008103 glucose Substances 0.000 description 31
239000000243 solution Substances 0.000 description 24
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 18
239000003814 drug Substances 0.000 description 17
229940079593 drug Drugs 0.000 description 16
238000001727 in vivo Methods 0.000 description 16
230000035515 penetration Effects 0.000 description 16
235000018102 proteins Nutrition 0.000 description 16
238000000338 in vitro Methods 0.000 description 15
210000004027 cell Anatomy 0.000 description 13
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 13
238000000034 method Methods 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
239000008280 blood Substances 0.000 description 11
210000004369 blood Anatomy 0.000 description 11
230000009467 reduction Effects 0.000 description 11
101000976075 Homo sapiens Insulin Proteins 0.000 description 10
230000003187 abdominal effect Effects 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
239000002674 ointment Substances 0.000 description 10
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
238000009792 diffusion process Methods 0.000 description 9
229960003180 glutathione Drugs 0.000 description 9
238000011282 treatment Methods 0.000 description 9
230000000052 comparative effect Effects 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 8
229940084769 humulin r Drugs 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
206010012601 diabetes mellitus Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
238000012453 sprague-dawley rat model Methods 0.000 description 5
230000032258 transport Effects 0.000 description 5
108010024636 Glutathione Proteins 0.000 description 4
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
210000001015 abdomen Anatomy 0.000 description 4
238000010241 blood sampling Methods 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
230000002500 effect on skin Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000003292 glue Substances 0.000 description 4
235000003969 glutathione Nutrition 0.000 description 4
230000002779 inactivation Effects 0.000 description 4
229960001412 pentobarbital Drugs 0.000 description 4
229960002275 pentobarbital sodium Drugs 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
229910052710 silicon Inorganic materials 0.000 description 4
239000010703 silicon Substances 0.000 description 4
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
IEPRKVQEAMIZSS-WAYWQWQTSA-N Diethyl maleate Chemical compound CCOC(=O)\C=C/C(=O)OCC IEPRKVQEAMIZSS-WAYWQWQTSA-N 0.000 description 3
108010053070 Glutathione Disulfide Proteins 0.000 description 3
230000036983 biotransformation Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000003961 penetration enhancing agent Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000012286 potassium permanganate Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000005070 sampling Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
101150018711 AASS gene Proteins 0.000 description 2
IEPRKVQEAMIZSS-UHFFFAOYSA-N Di-Et ester-Fumaric acid Natural products CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 2
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
239000002998 adhesive polymer Substances 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
210000004207 dermis Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 2
NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
102100025841 Cholecystokinin Human genes 0.000 description 1
101800001982 Cholecystokinin Proteins 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
102000051325 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
108010063907 Glutathione Reductase Proteins 0.000 description 1
102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
UQKKDJWFQBNZBJ-UHFFFAOYSA-N Polydin Natural products OC1C(O)C(O)COC1OC1=CC(O)=C(CC(O)C(O2)C=3C=C(O)C(O)=CC=3)C2=C1 UQKKDJWFQBNZBJ-UHFFFAOYSA-N 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920002396 Polyurea Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000011149 active material Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
229940078916 carbamide peroxide Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940107137 cholecystokinin Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
230000036576 dermal application Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000010932 ethanolysis reaction Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000004907 flux Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
230000006377 glucose transport Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229940045644 human calcitonin Drugs 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229940063718 lodine Drugs 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
108700009872 mild silver Proteins 0.000 description 1
229940037310 mild silver protein Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
230000001012 protector Effects 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
229940124272 protein stabilizer Drugs 0.000 description 1
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
108010068072 salmon calcitonin Proteins 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
231100000245 skin permeability Toxicity 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000000434 stratum corneum Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
210000004003 subcutaneous fat Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229940126703 systemic medication Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
WBGSMIRITKHZNA-UHFFFAOYSA-M trisodium;dioxido(oxidooxy)borane Chemical compound [Na+].[Na+].[Na+].[O-]OB([O-])[O-] WBGSMIRITKHZNA-UHFFFAOYSA-M 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL12094397A 1997-05-29 1997-05-29 מערכת למתן תרופות דרך העור IL120943A (he)

Priority Applications (8)

Application Number	Priority Date	Filing Date	Title
IL12094397A IL120943A (he)	1997-05-29	1997-05-29	מערכת למתן תרופות דרך העור
US09/424,525 US6274166B1 (en)	1997-05-29	1998-05-04	Transdermal delivery system
AU70770/98A AU7077098A (en)	1997-05-29	1998-05-04	Transdermal delivery system
JP50043099A JP2002501524A (ja)	1997-05-29	1998-05-04	経皮送達系
DE69832055T DE69832055T2 (de)	1997-05-29	1998-05-04	Transdermales abgabesystem
EP98917589A EP0975357B1 (en)	1997-05-29	1998-05-04	Transdermal delivery system
PCT/IL1998/000205 WO1998053847A1 (en)	1997-05-29	1998-05-04	Transdermal delivery system
US09/928,131 US6667052B2 (en)	1997-05-29	2001-08-10	Transdermal delivery system

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL12094397A IL120943A (he)	1997-05-29	1997-05-29	מערכת למתן תרופות דרך העור

Publications (2)

Publication Number	Publication Date
IL120943A0 IL120943A0 (en)	1997-09-30
IL120943A true IL120943A (he)	2004-03-28

Family

ID=11070190

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12094397A IL120943A (he)	1997-05-29	1997-05-29	מערכת למתן תרופות דרך העור

Country Status (7)

Country	Link
US (1)	US6274166B1 (he)
EP (1)	EP0975357B1 (he)
JP (1)	JP2002501524A (he)
AU (1)	AU7077098A (he)
DE (1)	DE69832055T2 (he)
IL (1)	IL120943A (he)
WO (1)	WO1998053847A1 (he)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6667052B2 (en) *	1997-05-29	2003-12-23	Ben Gurion University Of The Negev Research And Development Authority	Transdermal delivery system
US6183773B1 (en) *	1999-01-04	2001-02-06	The General Hospital Corporation	Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
EP1148902A1 (en) *	1999-01-22	2001-10-31	PowderJect Research Limited	Method of enhancing needleless transdermal powdered drug delivery
US7288390B2 (en)	2000-08-07	2007-10-30	Centocor, Inc.	Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en)	2000-08-07	2005-06-07	Centocor, Inc.	Anti-IL-12 antibodies and compositions thereof
JP2004506005A (ja)	2000-08-16	2004-02-26	ザ　ジェネラル　ホスピタル　コーポレイション　ディー　ビー　エイ　マサチューセッツ　ジェネラル　ホスピタル	尋常性挫瘡用の局所アミノレブリン酸−光力学的治療
RU2318829C2 (ru)	2001-11-14	2008-03-10	Сентокор, Инк.	Антитела против il-6, композиции, способы и применение
US8623822B2 (en)	2002-03-01	2014-01-07	Bracco Suisse Sa	KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en)	2002-03-01	2007-05-01	Bracco International B.V.	Multivalent constructs for therapeutic and diagnostic applications
AU2003213730A1 (en)	2002-03-01	2003-09-16	Bracco International B.V.	Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en)	2002-03-01	2007-08-28	Bracco International Bv	Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) *	2002-03-01	2010-09-14	Bracco International B.V.	Targeting vector-phospholipid conjugates
EP1587944A4 (en)	2002-03-01	2007-03-21	Dyax Corp	KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
CA2490409A1 (en)	2002-06-28	2004-01-08	Centocor, Inc.	Mammalian ch1 deleted mimetibodies, compositions, methods and uses
IL152574A (he) *	2002-10-31	2009-09-22	Transpharma Medical Ltd	מערכת להולכה דרך העור של פריטים יבשים או תרופות מיובשות
US8133505B2 (en) *	2002-10-31	2012-03-13	Transpharma Medical Ltd.	Transdermal delivery system for dried particulate or lyophilized medications
US7383084B2 (en) *	2002-10-31	2008-06-03	Transpharma Medical Ltd.	Transdermal delivery system for dried particulate or lyophilized medications
US7662404B2 (en) *	2002-10-31	2010-02-16	Transpharma Medical Ltd.	Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
EP2284180B1 (en)	2003-03-03	2015-09-09	Dyax Corp.	Uses of peptides that specifically bind HGF receptor (cMET)
US8524272B2 (en)	2003-08-15	2013-09-03	Mylan Technologies, Inc.	Transdermal patch incorporating active agent migration barrier layer
UA89481C2 (uk)	2003-09-30	2010-02-10	Центокор, Инк.	Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
EA011583B1 (ru)	2004-03-31	2009-04-28	Сентокор, Инк.	Миметические антитела glp-1 человека, композиции, способы и применения
JP5007427B2 (ja) *	2004-05-13	2012-08-22	アルザコーポレイション	副甲状腺ホルモン剤の経皮送達のための装置および方法
US7393662B2 (en)	2004-09-03	2008-07-01	Centocor, Inc.	Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
PA8672101A1 (es)	2005-04-29	2006-12-07	Centocor Inc	Anticuerpos anti-il-6, composiciones, métodos y usos
EP2452694B1 (en)	2005-06-30	2018-11-14	Janssen Biotech, Inc.	Anti-IL-23 antibodies, compositions, methods and uses
RS55963B1 (sr)	2005-12-29	2017-09-29	Janssen Biotech Inc	Humana anti-il-23 antitela, kompozicije, metode i upotrebe
TW200843794A (en)	2006-12-21	2008-11-16	Centocor Inc	Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
CA2724949A1 (en)	2007-06-27	2008-12-31	The General Hospital Corporation	Method and apparatus for optical inhibition of photodynamic therapy
US7883487B2 (en) *	2008-06-16	2011-02-08	Shantha Totada R	Transdermal local anesthetic patch with injection port
BRPI0919881B1 (pt)	2008-10-31	2021-09-08	Centocor Ortho Biotech Inc	Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
WO2010093627A2 (en)	2009-02-12	2010-08-19	Centocor Ortho Biotech Inc.	Fibronectin type iii domain based scaffold compositions, methods and uses
CA2796567C (en)	2010-03-31	2016-07-12	Wockhardt Limited	Composition comprising insulin and herbal oil for transdermal or transmucosal administration
ES2961381T3 (es)	2010-06-19	2024-03-11	Memorial Sloan Kettering Cancer Center	Anticuerpos anti-GD2
US9334306B2 (en)	2011-07-09	2016-05-10	The Regents Of The University Of California	Leukemia stem cell targeting ligands and methods of use
EP2846825B1 (en)	2012-03-14	2021-05-05	The Regents of The University of California	Treatment of inflammatory disorders in non-human mammals
US10414808B2 (en)	2012-05-18	2019-09-17	Janssen Biotech, Inc.	Huwentoxin-IV variants and methods of use
EP3973981A1 (en)	2012-05-18	2022-03-30	Janssen Biotech, Inc.	Huwentoxin-iv variants and methods of use
US10167341B2 (en)	2013-03-15	2019-01-01	Memorial Sloan Kettering Cancer Center	High affinity anti-GD2 antibodies
ES2841173T3 (es)	2013-10-03	2021-07-07	Janssen Biotech Inc	Variantes de Protoxina-II y métodos de uso
WO2015200790A2 (en)	2014-06-26	2015-12-30	Yale University	Compositions and methods to regulate renalase in the treatment of diseases and disorders
MA41642A (fr)	2015-03-03	2018-01-09	Janssen Biotech Inc	Variants de protoxine ii et méthodes d'utilisation
TW201708249A (zh)	2015-04-02	2017-03-01	健生生物科技公司	原毒素－ｉｉ變體及使用方法
EA201892190A1 (ru)	2016-03-29	2019-04-30	Янссен Байотек, Инк.	Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
CA3026757A1 (en)	2016-07-15	2018-01-18	Poseida Therapeutics, Inc.	Chimeric antigen receptors and methods for use
US20190328784A1 (en)	2016-07-15	2019-10-31	Poseida Therapeutics, Inc.	Chimeric antigen receptors (cars) specific for muc1 and methods for their use
EP3519049B1 (en)	2016-09-30	2025-12-03	Janssen Biotech, Inc.	Safe and effective method of treating psoriasis with anti-il23 specific antibody
MX2019005661A (es)	2016-11-16	2019-10-07	Janssen Biotech Inc	Método para tratar la psoriasis con el anticuerpo específico anti-il23.
JP2020506916A (ja)	2017-01-30	2020-03-05	ヤンセンバイオテツク，インコーポレーテツド	活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
EP3579871A4 (en)	2017-02-07	2021-07-21	Janssen Biotech, Inc.	ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS OF TREATMENT FOR ACTIVE BECHTEREW'S LIVER
US12385061B2 (en)	2017-09-08	2025-08-12	Poseida Therapeutics, Inc.	Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
TW201922780A (zh)	2017-09-25	2019-06-16	美商健生生物科技公司	以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US20190135910A1 (en)	2017-11-06	2019-05-09	Janssen Biotech, Inc.	Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
CA3086187A1 (en)	2017-12-20	2019-06-27	Poseida Therapeutics, Inc.	Vcar compositions and methods for use
ES3064335T3 (en)	2018-03-05	2026-04-24	Janssen Biotech Inc	Methods of treating crohn's disease with anti-il23 specific antibody
WO2019173636A1 (en)	2018-03-07	2019-09-12	Poseida Therapeutics, Inc.	Cartyrin compositions and methods for use
JP2021523138A (ja)	2018-05-11	2021-09-02	ヤンセンバイオテツク，インコーポレーテツド	Ｉｌ−２３抗体を使用してうつを治療する方法
JP7634474B2 (ja)	2018-07-18	2025-02-21	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
PL3883606T3 (pl)	2018-09-24	2023-11-27	Janssen Biotech, Inc.	Bezpieczny i skuteczny sposób leczenia wrzodziejącego zapalenia jelita grubego przeciwciałami anty-il12/il23
MX2021005905A (es)	2018-11-20	2021-06-23	Janssen Biotech Inc	Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
JP2022514561A (ja)	2018-12-18	2022-02-14	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
CN113498439A (zh)	2018-12-20	2021-10-12	波赛达治疗公司	纳米转座子组合物及使用方法
JP7689074B2 (ja)	2019-01-15	2025-06-05	ヤンセンバイオテツク，インコーポレーテツド	若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
CN113330031A (zh)	2019-01-23	2021-08-31	詹森生物科技公司	用于在治疗银屑病关节炎的方法中使用的抗tnf抗体组合物
WO2020183269A1 (en)	2019-03-14	2020-09-17	Janssen Biotech, Inc.	Manufacturing methods for producing anti-tnf antibody compositions
JP7635137B2 (ja)	2019-03-14	2025-02-25	ヤンセンバイオテツク，インコーポレーテツド	抗ｔｎｆ抗体組成物を産生するための方法
WO2020183418A1 (en)	2019-03-14	2020-09-17	Janssen Biotech, Inc.	Manufacturing methods for producing anti-il12/il23 antibody compositions
CN113840837A (zh)	2019-03-14	2021-12-24	詹森生物科技公司	用于产生抗tnf抗体组合物的方法
AU2020243588C1 (en)	2019-03-18	2026-04-02	Janssen Biotech, Inc.	Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody
US11780911B2 (en)	2019-05-23	2023-10-10	Janssen Biotech, Inc.	Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
KR20220030952A (ko)	2019-06-03	2022-03-11	얀센 바이오테크 인코포레이티드	활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
CA3142665A1 (en)	2019-06-03	2020-12-10	Janssen Biotech, Inc.	Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
JP2022536088A (ja)	2019-06-04	2022-08-12	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
WO2021028752A1 (en)	2019-08-15	2021-02-18	Janssen Biotech, Inc.	Anti-tfn antibodies for treating type i diabetes
WO2021046261A1 (en)	2019-09-05	2021-03-11	Poseida Therapeutics, Inc.	Allogeneic cell compositions and methods of use
AU2020407235A1 (en)	2019-12-20	2022-07-07	Poseida Therapeutics, Inc.	Anti-MUC1 compositions and methods of use
RU2745998C1 (ru) *	2020-01-17	2021-04-05	Акционерное Общество "Производственная Фармацевтическая Компания Обновление"	Биоадгезивная антибактериальная композиция, способ ее изготовления (варианты)
WO2021178707A1 (en)	2020-03-04	2021-09-10	Poseida Therapeutics, Inc.	Compositions and methods for the treatment of metabolic liver disorders
WO2021183795A1 (en)	2020-03-11	2021-09-16	Poseida Therapeutics, Inc.	Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
WO2021211628A1 (en)	2020-04-14	2021-10-21	Poseida Therapeutics, Inc.	Compositions and methods for use in the treatment of cancer
WO2021214588A1 (en)	2020-04-21	2021-10-28	Janssen Biotech, Inc.	Anti-tnf alpha agent for treating coronavirus infections
WO2021214587A1 (en)	2020-04-21	2021-10-28	Janssen Biotech, Inc.	Anti-tnf alpha agent for treating viral infections
JP2023524125A (ja)	2020-05-05	2023-06-08	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ２３特異的抗体によるクローン病の治療方法
MX2022014430A (es)	2020-05-21	2023-02-22	Janssen Biotech Inc	Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
US20210386698A1 (en) *	2020-06-16	2021-12-16	Sailendra Nath Nichenametla	Compositions and Methods for Preventing or Treating Diseases or Disorders Associated with Protein Misfolding
CA3189402A1 (en)	2020-07-13	2022-01-20	Janssen Biotech, Inc.	Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
WO2022024065A1 (en)	2020-07-30	2022-02-03	Janssen Biotech, Inc.	Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
US20240060090A1 (en)	2021-02-23	2024-02-22	Poseida Therapeutics, Inc.	Genetically modified induced pluripotent stem cells and methods of use thereof
WO2022187671A1 (en)	2021-03-04	2022-09-09	Poseida Therapeutics, Inc.	Compositions and methods for the treatment of hemophilia
CA3212729A1 (en)	2021-03-12	2022-09-15	Janssen Biotech, Inc.	Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
AU2022232007A1 (en)	2021-03-12	2023-10-26	Janssen Biotech, Inc.	Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
CN117957251A (zh)	2021-07-09	2024-04-30	詹森生物科技公司	用于制备抗tnf抗体组合物的制造方法
WO2023281466A1 (en)	2021-07-09	2023-01-12	Janssen Biotech, Inc.	Manufacturing methods for producing anti-il12/il23 antibody compositions
CN118139883A (zh)	2021-07-09	2024-06-04	詹森生物科技公司	用于生产抗tnf抗体组合物的制造方法
WO2023041985A2 (en)	2021-09-15	2023-03-23	New York University In Abu Dhabicorporation	Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
US20240401085A1 (en)	2021-10-04	2024-12-05	Poseida Therapeutics, Inc.	Transposon compositions and methods of use thereof
AU2022374890A1 (en)	2021-10-29	2024-06-13	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
CA3238377A1 (en)	2021-11-15	2023-05-19	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
US20230159633A1 (en)	2021-11-23	2023-05-25	Janssen Biotech, Inc.	Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
EP4482967A1 (en)	2022-02-23	2025-01-01	Poseida Therapeutics, Inc.	Genetically modified cells and methods of use thereof
CA3258517A1 (en)	2022-03-30	2023-10-05	Janssen Biotech, Inc.	TREATMENT METHOD FOR MILD TO MODERATE PSORIASIS WITH A SPECIFIC IL-23 ANTIBODY
WO2023193010A1 (en)	2022-04-01	2023-10-05	The Regents Of The University Of California	Methods of improving cancer immunotherapy
KR20250011938A (ko)	2022-05-18	2025-01-22	얀센 바이오테크 인코포레이티드	Il23 항체에 의해 건선성 관절염을 평가 및 치료하기 위한 방법
JP2025528163A (ja)	2022-08-11	2025-08-26	ポセイダセラピューティクス，インコーポレイティド	キメラｃｄ８－アルファ補助受容体組成物及び使用方法
JP2025539830A (ja)	2022-11-22	2025-12-09	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ２３特異的抗体で潰瘍性大腸炎を治療する方法
AU2024224841A1 (en)	2023-02-21	2025-08-21	Poseida Therapeutics, Inc.	Aav piggybac transposon polynucleotide compositions and methods of use therefor
JP2026507648A (ja)	2023-02-21	2026-03-04	ポセイダセラピューティクス，インコーポレイティド	ゲノム編集のための組成物及び方法
JP2026507731A (ja)	2023-02-21	2026-03-04	ポセイダセラピューティクス，インコーポレイティド	ゲノム編集のための組成物及び方法
IL327036A (he)	2023-09-19	2026-05-01	Poseida Therapeutics Inc	הרכבים ושיטות לשילוב של וקטורים ויראליים
WO2025068976A1 (en) *	2023-09-28	2025-04-03	Biotts Inc.	Compositions comprising insulin agonists, and said compositions for use in the treatment of diabetes or obesity
CA3249015A1 (en)	2024-03-20	2025-10-31	Janssen Biotech, Inc.	Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025217124A1 (en)	2024-04-09	2025-10-16	Beth Israel Deaconess Medical Center, Inc.	An inhibitor of soluble epoxide hydrolase for use in the treatment of cancer cachexia
WO2025262604A1 (en)	2024-06-17	2025-12-26	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
CA3258952A1 (en)	2024-06-27	2026-03-01	Janssen Biotech, Inc.	Methods of treating ulcerative colitis with anti-il23 specific antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4229410A (en) *	1978-02-13	1980-10-21	Kosti Carl M	Bacteriostatic deodorant water coloring toilet element
LU84485A1 (fr) *	1982-11-22	1984-06-13	Oreal	Nouvelle composition anti-acneique a base de peroxyde de benzoyle et d'au moins un autre principe actif
AU4292585A (en) *	1984-04-30	1985-11-28	Trustees Of Columbia University In The City Of New York, The	Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
AU4035989A (en) *	1988-07-19	1990-02-19	American Biogenetics Corporation	Method for solubilizing keratinaceous materials using alkaline hydrogen peroxide solution
ATE118350T1 (de) *	1988-07-22	1995-03-15	Morris John Co Inc	Zusammensetzungen und verfahren zur behandlung von hautkrankheiten und zur aktivierung der wundheilung.
US5707641A (en) *	1994-10-13	1998-01-13	Pharmaderm Research & Development Ltd.	Formulations comprising therapeutically-active proteins or polypeptides

1997
- 1997-05-29 IL IL12094397A patent/IL120943A/he not_active IP Right Cessation
1998
- 1998-05-04 DE DE69832055T patent/DE69832055T2/de not_active Expired - Lifetime
- 1998-05-04 AU AU70770/98A patent/AU7077098A/en not_active Abandoned
- 1998-05-04 EP EP98917589A patent/EP0975357B1/en not_active Expired - Lifetime
- 1998-05-04 US US09/424,525 patent/US6274166B1/en not_active Expired - Fee Related
- 1998-05-04 WO PCT/IL1998/000205 patent/WO1998053847A1/en not_active Ceased
- 1998-05-04 JP JP50043099A patent/JP2002501524A/ja active Pending

Also Published As

Publication number	Publication date
DE69832055D1 (de)	2005-12-01
DE69832055T2 (de)	2006-07-20
JP2002501524A (ja)	2002-01-15
AU7077098A (en)	1998-12-30
US6274166B1 (en)	2001-08-14
EP0975357B1 (en)	2005-10-26
EP0975357A1 (en)	2000-02-02
IL120943A0 (en)	1997-09-30
WO1998053847A1 (en)	1998-12-03

Legal Events

Date	Code	Title
2004-09-27	KB	Patent renewed
2007-07-24	KB	Patent renewed
2012-02-29	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0975357B1 (en)	2005-10-26	Transdermal delivery system
EP1556134B1 (en)	2015-08-26	Transdermal delivery system for dried particulate medications
EP1691823B1 (en)	2012-10-10	Transdermal system for sustained delivery of polypeptides
EP0727221A2 (en)	1996-08-21	Composition of ionizing solvent
EP0643981B1 (en)	2002-01-09	A matrix for iontophoreses
US20090175840A1 (en)	2009-07-09	Insulin formulations for insulin release as a function of tissue glucose levels
CA2502146A1 (en)	2005-09-30	Solution formulations of sirolimus and its analogs for cad treatment
WO1994010987A1 (en)	1994-05-26	Combined analgesic delivery methods for pain management
WO1985005036A1 (en)	1985-11-21	Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
US6667052B2 (en)	2003-12-23	Transdermal delivery system
Golomb et al.	1993	A new route of drug administration: intrauterine delivery of insulin and calcitonin
RU2543635C2 (ru)	2015-03-10	Способ и фармацевтические композиции для лечения постпрандиальной гипергликемии диабета ii типа введением через слизистую ротовой полости
US20050118241A1 (en)	2005-06-02	Platform for transdermal formulations (ptf)
NZ504806A (en)	2001-09-28	Transmucosal formulations of levosimendan
Chien et al.	1989	Potential developments in systemic delivery of insulin
Chien	1991	Systemic delivery of pharmacologically active molecules across the skin
Banga et al.	1993	Dermal absorption of peptides and proteins
HU223205B1 (hu)	2004-03-29	Helyileg alkalmazható készítmény peptidszerű gyógyhatású vegyületek élő szervezetbe vitelére
JPH10265405A (ja)	1998-10-06	インスリン含有の皮膚外用製剤
Starr	2000	Innovations in drug delivery.
KR930000062B1 (ko)	1993-01-08	단백 및 펩타이드성 약물의 경피투여조성물
Maqbool et al.	2025	UNLOCKING THE POTENTIAL OF TRANSDERMAL DRUG DELIVERY FOR EFFECTIVE DIABETES CONTROL: A REVIEW
US20160367791A1 (en)	2016-12-22	Transdermal System for Sustained Delivery of Polypeptides
Lin et al.	2013	Drug delivery: controlled release
US20250360156A1 (en)	2025-11-27	Synergistic combination of nad+ and therapeutic peptides delivered via iontophoresis for enhanced and prolonged regenerative effects